The original study made a striking claim. By profiling the genomic landscape of stage II melanoma, the researchers identified deletions at chromosomal region 11q23.1-q23.3 as a potential prognostic marker in RAS-mutant melanoma, and they reported an enrichment of small variants in CBL, particularly within the NF1 molecular subtype of the disease. Because CBL encodes an E3 ubiquitin ligase that negatively regulates receptor tyrosine kinase and MAPK signalling, the same pathway that drives melanoma through BRAF, NRAS and NF1 alterations, the gene is a plausible candidate. Losing a brake on this pathway could, in principle, fuel tumour growth. The study also reported a significant mutation hotspot at positions 417 and 418 in the RING finger domain of the protein, the structural element that gives the ubiquitin ligase its catalytic power, and robust in-silico predictions that these changes are damaging.

Poon and Koay do not dispute that CBL deserves attention. Their concern is that plausibility is not proof, and that the presentation of the variant data in the original paper leaves too many questions unanswered for the driver label to stand. Their critique begins with a deceptively simple technical point: the variants in the study’s main table were reported using only protein-level nomenclature, without the corresponding cDNA descriptions. Without cDNA notation, independent researchers cannot reliably verify the exact nucleotide changes, cross-reference databases, or reproduce the analysis. In a field where reproducibility is the currency of credibility, that omission matters.

The second concern cuts deeper. No variant allele frequencies were provided for the CBL mutations. Variant allele frequency, the fraction of sequencing reads carrying the mutant allele, is the primary tool for judging whether a variant is clonal, present in most tumour cells and therefore likely an early, cancer-relevant event, or subclonal and possibly a passenger. It is also the first line of defence against sequencing artefacts. This is especially important because the original study relied on formalin-fixed paraffin-embedded tissue, the standard archival material in pathology but notoriously prone to chemical damage that can generate false-positive mutations. Without allele frequency data, readers cannot distinguish a genuine tumour mutation from an artefact of fixation and sequencing chemistry.

The copy-number context of some variants raises further puzzles. Several CBL variants coexisted with heterozygous deletions of the region, a pattern consistent with a loss-of-function driver, since deleting the remaining copy of a tumour-suppressor-like gene is a classic two-hit mechanism. But one case showed coexistence with an amplification instead. For a hypothesised loss-of-function driver, amplification of the very locus supposed to be inactivated is biologically incongruous, and it forces the question of what CBL is actually doing in that tumour. The gene’s role may be context-dependent: in some settings CBL loss promotes signalling, while in others CBL has been implicated in oncogenic functions, which complicates any simple narrative.

Database evidence also came under scrutiny. The COSMIC catalogue counts cited in support of the variants were not consistently melanoma-specific, meaning mutations observed in entirely different tumour types were being marshalled as evidence of relevance in skin cancer. Similarly, the OncoKB classifications used to argue oncogenicity were based on evidence from other cancers. A variant that is oncogenic in myeloid leukaemia or another CBL-linked malignancy is not automatically oncogenic in melanoma, where cellular context, co-mutations and selective pressures differ profoundly. Cross-cancer evidence can generate hypotheses, Poon and Koay argue, but it cannot substitute for melanoma-specific proof.

Perhaps the most statistically pointed objection concerns recurrence, a cornerstone criterion for driver nomination. Genuine drivers are hit repeatedly by tumours because mutating them confers a selective growth advantage, the defining idea that Stratton, Campbell and Futreal articulated in their landmark 2009 Nature paper on the cancer genome. Yet of the 24 CBL variants found across 20 tumours in the study, 21 were unique. That near-total absence of the same variant appearing twice sits uneasily with driver status and suggests the enrichment signal may be driven by aggregation of heterogeneous, individually rare alterations rather than by repeated targeting of functionally critical residues. The correspondents also ask whether excluding variants of uncertain significance, the notorious VUS category, from the enrichment analysis would change the statistical significance of CBL as a driver. Including unclassified variants in such calculations can inflate or bias statistical signals, since VUS have not been shown to alter protein function at all.

Underlying the entire exchange is a structural gap in the variant-interpretation infrastructure. No ClinGen Gene Curation Expert Panel currently exists for CBL, the specialised bodies that convene to establish rigorous, gene-specific rules for judging pathogenicity. In their absence, interpretation of CBL variants must lean on general somatic variant guidelines, including the joint consensus recommendations of the Association for Molecular Pathology, the American Society of Clinical Oncology and the College of American Pathologists, and the more recent oncogenicity standards from ClinGen, the Cancer Genomics Consortium and the Variant Interpretation for Cancer Consortium. Those frameworks are powerful, but they are designed to be applied variant by variant with careful evidence weighing, not to rubber-stamp an entire gene as a driver on the strength of an enrichment statistic.

The stakes extend well beyond an academic quarrel. Driver gene designations shape prognostic stratification, therapeutic development and, eventually, clinical decision-making. If CBL deletions at 11q23.1-q23.3 genuinely mark aggressive RAS-mutant stage II melanomas, patients carrying them might be candidates for intensified surveillance or adjuvant therapy, and the CBL protein itself, as a regulator of RTK-MAPK signalling, could become a drug target. But if the signal is an artefact of FFPE sequencing, unverified nomenclature, cross-cancer evidence borrowing and VUS-inflated statistics, then building a biomarker on it risks misclassifying patients. The distinction between driver and passenger is not a stylistic preference; it is the foundational inference of cancer genomics, and it demands evidence that an alteration actually confers a selective growth advantage.

The path forward, as Poon and Koay make clear, runs through the laboratory rather than through larger statistical models. Functional studies are needed to validate the oncogenicity of the specific CBL variants, particularly the RING finger hotspot at positions 417 and 418, in melanoma-relevant cellular contexts. Variant-level interpretation should follow established somatic classification standards, with cDNA-level reporting, allele frequency transparency, melanoma-specific database comparisons and careful handling of copy-number co-occurrence. Until such work is done, the correspondents conclude, CBL should be regarded as a candidate requiring validation rather than an established driver in melanoma. Their letter is a reminder that in precision oncology, the hardest step is often not finding a candidate gene but proving that the tumour, and not the method, put the mutation there.

Subject of Research: Variant interpretation and driver gene designation for CBL in stage II melanoma

Article Title: CBL in stage II melanoma: considerations of variant interpretation for driver gene designation

Article References: Poon, K.-S., & Koay, E. S.-C. (2026). CBL in stage II melanoma: considerations of variant interpretation for driver gene designation. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03629-1

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03629-1

Keywords: CBL, stage II melanoma, driver genes, variant interpretation, cancer genomics, 11q23 deletions, RTK-MAPK signalling, VUS, FFPE artefacts, ClinGen, OncoKB, British Journal of Cancer

Colorectal cancer, particularly in its advanced stages, often exhibits resistance to standard chemotherapeutic agents such as oxaliplatin. This resistance can be attributed to various cellular mechanisms, one of which involves the dysregulation of iron homeostasis within cancer cells. The research team investigated how FBXL5, an E3 ubiquitin ligase, interacts with iron metabolism and affects the cellular responses to oxidative stress induced by chemotherapeutic agents. Their compelling evidence suggests that FBXL5 not only regulates iron levels but also plays a crucial role in modulating the sensitivity of colorectal cancer cells to oxaliplatin.

Ferroptosis, characterized by the accumulation of lipid peroxides to lethal levels, has recently emerged as an exciting avenue for targeted cancer therapies. Unlike apoptosis and other forms of cell death, ferroptosis is iron-dependent and is uniquely triggered by factors such as glutathione depletion and the inhibition of certain metabolic pathways. The researchers provided substantial insights into how they intend to harness ferroptosis as a means of overcoming drug resistance. By inducing this form of cell death in iron-rich colorectal cancer cells, they aimed to improve the lethality of oxaliplatin-based therapies.

In-depth examination revealed that FBXL5 expression levels are significantly altered in various colorectal cancer cell lines, particularly those exhibiting resistance to oxaliplatin. The researchers meticulously documented the effects of silencing FBXL5 through RNA interference, which resulted in a remarkable increase in ferroptosis markers and a decrease in cell viability. This finding solidifies the role of FBXL5 as a double-edged sword; not only is it a facilitator of iron accumulation, but its expression also promotes a survival advantage for cancer cells in the presence of chemotherapeutics.

The methodological framework employed in the study included a robust combination of in vitro and in vivo experiments, allowing the team to visualize the consequences of FBXL5 modulation on tumor progression. Their analysis encompassed the use of common colorectal cancer models followed by detailed examinations of cell morphology, viability assays, and lipid peroxidation assessments. Each step of their research reinforced the hypothesis that targeting FBXL5 could be integral to enhancing ferroptosis induction, thereby curbing the proliferation of resistant colorectal cancer cells.

Additionally, the researchers investigated potential combinatorial treatments that employ FBXL5 inhibition alongside standard chemotherapy agents. This synergy could strategically sensitize resistant cells, making them more susceptible to traditional treatments. The compelling notion that ferroptosis can serve as an adjunct to existing therapies could revolutionize current treatment frameworks, providing oncologists with a powerful arsenal to combat treatment-resistant cancers.

As the implications of the study unfold, it becomes increasingly clear that targeting FBXL5 could not only confer therapeutic benefits but might also facilitate better patient stratification based on tumor iron levels. Future trials may seek to establish predictive biomarkers for ferroptosis sensitivity and evaluate whether patients with heightened FBXL5 expression might derive greater benefit from therapies that exploit this vulnerability. Such advancements could help tailor personalized treatment protocols, promoting more effective responses while minimizing unnecessary toxicity.

Furthermore, the research underscores the importance of understanding the complex interplay between iron metabolism and cancer biology. Colorectal tumors are uniquely capable of altering cellular iron homeostasis, which often contributes to medication resistance. This study emphasizes the critical need to further explore how harnessing the pathways associated with iron metabolism can lead to novel and effective therapeutic interventions. The team encourages continued investigation into the mechanistic underpinnings of iron-related cell death, as it holds promise for enhancing treatment efficacy across various oncological disciplines.

Looking ahead, the potential for clinical translation remains a key point of interest as the study lays the groundwork for future exploration. Understanding the role of FBXL5 in iron-overloaded environments could lead to the development of targeted drugs that enhance ferroptosis selectively within tumor cells, sparing normal tissues from harm. Collaboration between molecular biologists, oncologists, and pharmacologists will be essential to navigate the complexities of translating these findings from bench to bedside effectively.

In conclusion, the work presented by Wang et al. is not merely an academic exercise; it represents a significant leap towards redefining therapeutic strategies for iron-rich colorectal cancer. By effectively targeting FBXL5, the authors provide a compelling case for inducing ferroptosis as a means to reverse oxaliplatin resistance, potentially transforming outcomes for countless patients battling this formidable foe. This study not only ignites conversations in the scientific community about the intricacies of iron metabolism in cancer but also emphasizes the importance of innovation in therapeutic development.

As research efforts propel forward, there remains an optimistic outlook for integrating ferroptosis in treatment regimens, particularly in synergism with existing chemotherapeutic strategies. The vision extends beyond colorectal cancer, hinting at the broader applicability of this approach to other malignancies characterized by similar iron dynamics. Ultimately, as the clinical and molecular landscapes collide, the potential to reshape cancer therapeutics is within reach, promising hope and clarity amidst the ongoing struggle against oncological resistance.

In a world where cancer remains a leading cause of death, the exploration of innovative pathways such as those presented by Wang et al. offers a glimmer of hope. The pursuit of better strategies to combat drug resistance could soon elevate the standards of care in oncology, ushering in a new era of effective, tailored treatments that leverage the biological idiosyncrasies of tumors to outsmart their survival mechanisms.

Subject of Research: Iron-rich colorectal cancer, oxaliplatin resistance, and ferroptosis.

Article Title: Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer.

Article References:

Wang, M., Zhang, R., He, S. et al. Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer. Sci Rep 15, 37189 (2025). https://doi.org/10.1038/s41598-025-14086-w

Image Credits: AI Generated

DOI: 10.1038/s41598-025-14086-w

Keywords: Ferroptosis, FBXL5, Colorectal cancer, Oxaliplatin resistance, Iron metabolism.